The CSL share price is up 25% in 12 months

The CSL Limited (ASX:CSL) share price is up 25% in 12 months. Is it too late to invest?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

On Thursday the CSL Limited (ASX: CSL) share price dropped 1% lower to finish the day at $1.99.

Despite this small decline, the biotherapeutics company's shares are up an impressive 25% over the last 12 months.

Why is the CSL share price up 25% in 12 months?

The CSL share price has been on fire over the last 12 months thanks to an impressive performance in FY 2018 and an equally positive start to FY 2019.

The company posted a net profit after tax of US$1,729 million in FY 2018, which was up by 29% on the prior corresponding period. This was driven by strong sales of its Privigen, Hizentra, and IDELVION products and supported by the launch of the HAEGARDA product.

The good news for shareholders is that the positive momentum has carried over into FY 2019 with the company releasing a solid half year result in February.

CSL posted a 9% increase in total half year revenue to US$4.5 billion and a 7% (10% in constant currency) increase in net profit after tax to US$1.2 billion.

The strong top line growth was the result of an 8% lift in revenue by its CSL Behring business and a 21% jump in revenue by its fledgling Seqirus influenza business.

Pleasingly, management also provided guidance which indicates that the second half will be even stronger.

It advised that the company is trending towards the upper end of its full year profit guidance range of US$1,880 million to US$1,950 million, which will mean year on year growth of approximately 13%.

Is it too late to invest?

Although its shares are not cheap at 33x estimated forward earnings, I think the quality of the business and its strong long term growth potential makes it deserving of this premium.

As a result, despite its strong share price rally over the 12 months, I would still class CSL as a buy along with fellow healthcare shares Cochlear Limited (ASX: COH) and ResMed Inc. (ASX: COH).

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. and CSL Ltd. The Motley Fool Australia has recommended Cochlear Ltd. and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Share Gainers

3 ASX All Ords shares up 50%+ in March

These ASX shares have been on fire this month. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Share Gainers

Why Mesoblast, Patriot Battery Metals, Sigma, and Zip shares are pushing higher

These shares are having a good session on hump day. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Consumer Staples & Discretionary Shares

If you'd put $20,000 in this ASX retail stock at the start of 2023, you'd have $134,000 now

This online retailer has executed a remarkable turnaround for its investors.

Read more »

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

It was back to earth for ASX shares this Tuesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »